ESR1 and breast cancer: Similarly, fulvestrant acts as tamoxifen, but it causes degradation of the ER protein and loss of estrogen and progesterone receptor expression.24 Menopausal hormone therapy usually restrained from breast cancer survivors because of the risk of reoccurrence.